Australia’s Minister for Health Tanya Plibersek has announced a major review into the way chemotherapy is funded and provided as a way of ensuring the nation’s cancer patients have continued access to quality, affordable treatment.
“Being diagnosed and treated for cancer is a traumatic experience for patients and their families,” Ms Plibersek said, adding: “The Gillard government wants to ensure cancer patients don’t experience any interruption in their treatment while we closely examine how much we should be paying to support the ongoing viability for chemotherapy providers.”
Ms Plibersek said the review followed talks between the government and the Pharmacy Guild of Australia over appropriate subsidies for dispensing chemotherapy after the reduction in price the government pays for a key chemotherapy drug, docetaxel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze